{
  "trial_id": "NCT04605991",
  "trial_group": "diabetes",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, duration of type 2 diabetes, HbA1c, body mass index (BMI), baseline insulin regimen, use of oral antihyperglycemic medications, use of GLP-1 receptor agonists, history of severe hypoglycemia, history of hyperglycemic hyperosmolar state, history of diabetic ketoacidosis, hypoglycemia awareness status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Percentage of Time With Sensor Glucose Values Between 70 and 180 mg/dL During Daytime Period",
          "Percentage of Time With Sensor Glucose Values Between 70 and 180 mg/dL During Daytime Period"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "duration of type 2 diabetes",
        "HbA1c",
        "body mass index (BMI)",
        "baseline insulin regimen",
        "use of oral antihyperglycemic medications",
        "use of GLP-1 receptor agonists",
        "history of severe hypoglycemia",
        "history of hyperglycemic hyperosmolar state",
        "history of diabetic ketoacidosis",
        "hypoglycemia awareness status."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Duration of Diabetes, Baseline HbA1c, Basal Insulin Dose, Bolus Insulin Dose, Use of Oral Antihyperglycemic Medications, Use of Injectable GLP-1 Receptor Agonist,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Percentage of Time With Sensor Glucose Values Between 70 and 180 mg/dL During Daytime Period"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Duration of Diabetes",
        "Baseline HbA1c",
        "Basal Insulin Dose",
        "Bolus Insulin Dose",
        "Use of Oral Antihyperglycemic Medications",
        "Use of Injectable GLP-1 Receptor Agonist"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Diabetes Duration, HbA1c, Body Mass Index, Systolic Blood Pressure, Diastolic Blood Pressure, Total Daily Insulin Dose, Basal Insulin Dose, Bolus Insulin Dose, Use of Oral Antihyperglycemic Medications.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Percentage of Time With Sensor Glucose Values Between 70 and 180 mg/dL During Daytime Period"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Diabetes Duration",
        "HbA1c",
        "Body Mass Index",
        "Systolic Blood Pressure",
        "Diastolic Blood Pressure",
        "Total Daily Insulin Dose",
        "Basal Insulin Dose",
        "Bolus Insulin Dose",
        "Use of Oral Antihyperglycemic Medications."
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, body mass index (BMI), duration of type 2 diabetes, HbA1c, fasting plasma glucose, insulin dose, oral antihyperglycemic medication use, injectable GLP-1 receptor agonist use, systolic blood pressure, diastolic blood pressure, history of hypoglycemia, history of hyperglycemic hyperosmolar state or diabetic ketoacidosis.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Percentage of Time With Sensor Glucose Values Between 70 and 180 mg/dL During Daytime Period",
          "Percentage of Time With Sensor Glucose Values Between 70 and 180 mg/dL During Daytime Period"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "body mass index (BMI)",
        "duration of type 2 diabetes",
        "HbA1c",
        "fasting plasma glucose",
        "insulin dose",
        "oral antihyperglycemic medication use",
        "injectable GLP-1 receptor agonist use",
        "systolic blood pressure",
        "diastolic blood pressure",
        "history of hypoglycemia",
        "history of hyperglycemic hyperosmolar state or diabetic ketoacidosis."
      ]
    }
  }
}